NEW YORK (GenomeWeb) – Led by a team from the Translational Genomics Research Institute, researchers are pushing forward to test whether circulating DNA mutations might be a better way to monitor the disease progress and drug responses of metastatic melanoma patients than current imaging tools.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.